Overview

Therapeutics based on harnessing the immune system is now a $230 billion industry globally. These therapeutics stem from the promise of using the specific antibodies formed for diagnostics and therapeutics purposes. The antibodies, or Immunologicals, now form the backbone of biotechnology in the form of diagnostics and therapeutics. This area has now matured and holds great promise for the treatment of a variety of diseases including cancer, autoimmune diseases and allergies. This course will trace the development of the technology, its intersection with biotechnology, and its current use in the clinic in animals and humans.

Last date for registration : June 22, 2016

Tentative Schedule

Course Details

DAYTITLE
July 4: Development of hybridoma technology and early sue of monoclonal antibodies
July 5: Genetic engineering of antibodies
July 6: Animal free generation of monoclonal antibodies
July 7: Humanization of antibodies
July 8: Antibody fusion proteins as therapeutics
July 9: Current antibody based therapeutics, their targets and indications
July 11: Current antibody based therapeutics, their targets and Indications (contd.)
July 12: Diagnostic antibodies for infectious diseases in animals and humans
July 13: Cancer diagnostic tools and technologies in animals and humans
July 14: Cancer diagnostic tools and technologies in animals and humans (contd.)
July 15: Target development
July 16: Antibody engineering exercise

Who can attend?

  • Researchers and Faculties at University, Government, and industrial laboratories.

  • Students at all levels (MSc/PhD) from academic and technical institutions.

How to apply?

Please submit your detailed resume along with statement of purpose. For more details contact : giandabsl@gmail.com or Click here.